Liglipex

Linagliptin, the active ingredient in Liglipex, is a Dipeptidyl peptidase-4 (DPP-4) inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults. GNH USA supplies Liglipex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used to improve glycaemic control in patients with type 2 diabetes mellitus. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose when combined with diet and exercise. - Monotherapy in adults: provides glycaemic reduction without the need for dose titration. - Combination therapy: can be added to metformin, sulfonylureas or insulin to achieve additional glucose lowering.

Adverse reactions reported with linagliptin are generally mild to moderate.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Headache: transient, mild to moderate intensity. - Dizziness: occasional light‑headedness, especially on standing. - Gastrointestinal upset: nausea, abdominal discomfort or diarrhoea. - Upper respiratory tract infection: cough or sore throat.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Hypoglycaemia: when combined with insulin or sulfonylureas. - Bullous skin disorders: rare blistering skin reactions.

Linagliptin should be used with awareness of specific safety considerations. - Renal impairment: no dose adjustment required, but monitor renal function regularly. - Hepatic impairment: use with caution in patients with moderate liver disease. - Cardiovascular disease: observe for any worsening of heart failure symptoms. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Elderly patients: monitor for dehydration and renal function. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin may interact with several medicines; awareness of interaction severity helps guide therapy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Combination with insulin or sulfonylureas: heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce linagliptin effectiveness. - Diuretics: can affect glucose control, requiring monitoring. - ACE inhibitors: monitor renal function and electrolytes when used together.